OPRX
OptimizeRx Corp.
$9.37
+0.44
(+4.93%)
Mkt Cap
176.49M
Volume
186,858
52W Range
4.54-22.25
Sector
Healthcare
Beta
1.09
EPS (TTM)
0.24 USD
P/E Ratio
38.46
Revenue (TTM)
98.65M USD
Rev Growth (5Y)
+20.4%
EPS Growth (5Y)
N/A
AlphaVal · Fair Value
What we estimate one share is worth
$88.05
Undervalued
strong signal
89.4% below fair value
Modeled from cash flows & growth.
AlphaQuality · Grade · Gated
How strong & durable the business is
F
Platform & Compounding FCF
30.0 / 100 pillar composite (overridden)
A platform business that compounds free cash flow — graded A–F vs. similar companies.
Company Description
OptimizeRx Corp. is digital health company, engaged in the provision of digital health messaging via electronic health records, which serve as a direct channel for pharmaceutical companies to communicate with healthcare providers. It offers electronic health record (EHR) workflow solutions which include financial messaging, patient education, and brand messaging and brand support. The company was founded by David A. Harrell in 2006 and is headquartered in Waltham, MA.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 109.43M | 92.13M | 71.52M | 62.45M | 61.29M | 43.31M | 24.60M | 21.21M | 12.13M | 7.75M | 7.22M | 6.50M |
| Net Income | 5.13M | (20.11M) | (17.57M) | (11.44M) | 378,079 | (2.21M) | (3.14M) | 226,344 | (2.10M) | (1.54M) | (595,140) | (1.03M) |
| EPS | 0.28 | -1.10 | -1.03 | -0.64 | 0.02 | -0.15 | -0.23 | 0.02 | -0.21 | -0.16 | -0.07 | -0.14 |
| Free Cash Flow | 18.66M | 4.78M | (8.11M) | 10.41M | 240,040 | (6.44M) | (3.25M) | 701,542 | (1.52M) | (815,503) | 414,146 | (466,302) |
| FCF / Share | 1.01 | 0.26 | -0.47 | 0.59 | 0.01 | -0.43 | -0.24 | 0.06 | -0.16 | -0.08 | 0.05 | -0.06 |
| Operating CF | 18.71M | 4.89M | (7.24M) | 10.65M | 726,039 | (6.31M) | (1.66M) | 792,555 | (1.48M) | (465,965) | 515,110 | (56,350) |
| Total Assets | 176.92M | 171.17M | 183.37M | 134.65M | 140.99M | 60.33M | 56.64M | 25.05M | 9.76M | 11.48M | 12.31M | 7.03M |
| Total Debt | 26.10M | 33.19M | 36.82M | 234,434 | 327,708 | 448,753 | 564,184 | 0 | 0 | 0 | 0 | 0 |
| Cash & Equiv | 23.36M | 13.38M | 13.85M | 18.21M | 84.68M | 10.52M | 18.85M | 8.91M | 5.12M | 7.03M | 8.21M | 3.45M |
| Book Value | 128.29M | 117.00M | 126.55M | 126.11M | 131.38M | 49.97M | 44.86M | 18.46M | 6.22M | 7.81M | 8.94M | 4.61M |
| Return on Equity | 0.04 | -0.17 | -0.14 | -0.09 | 0.00 | -0.04 | -0.07 | 0.01 | -0.34 | -0.20 | -0.07 | -0.22 |
| Metric | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 20.50M | 19.84M | 32.24M | 26.07M | 29.20M | 21.93M | 32.32M | 21.31M | 18.81M | 19.69M | 28.37M | 16.33M |
| Net Income | (703,000) | (495,000) | 5.02M | 779,000 | 1.53M | (2.20M) | (78,000) | (9.12M) | (4.01M) | (6.90M) | (4.14M) | (2.87M) |
| EPS | -0.04 | -0.03 | 0.27 | 0.04 | 0.08 | -0.12 | -0.00 | -0.50 | -0.22 | -0.38 | -0.23 | -0.17 |
| Free Cash Flow | 8.58M | (488,000) | 7.08M | 3.19M | 4.55M | 3.84M | 78,000 | 1.70M | 697,000 | 1.97M | (6.26M) | 1.15M |
| FCF / Share | 0.46 | -0.03 | 0.38 | 0.17 | 0.25 | 0.21 | 0.00 | 0.09 | 0.04 | 0.11 | -0.35 | 0.07 |
| Operating CF | 8.61M | (467,000) | 7.09M | 3.20M | 4.56M | 3.86M | 198,000 | 1.79M | 782,000 | 2.12M | (6.26M) | 1.47M |
| Total Assets | 164.32M | 167.26M | 176.92M | 170.32M | 169.26M | 167.77M | 171.17M | 165.20M | 172.88M | 176.37M | 183.37M | 123.93M |
| Total Debt | 19.48M | 23.72M | 26.10M | 28.61M | 28.98M | 32.80M | 33.19M | 35.72M | 36.09M | 36.46M | 36.82M | 148,642 |
| Cash & Equiv | 24.10M | 20.17M | 23.36M | 19.52M | 16.59M | 16.57M | 13.38M | 16.13M | 14.96M | 15.18M | 13.85M | 9.92M |
| Book Value | 131.08M | 129.61M | 128.29M | 122.26M | 119.28M | 116.27M | 117.00M | 114.47M | 121.02M | 122.54M | 126.55M | 116.11M |
| Return on Equity | -0.01 | -0.00 | 0.04 | 0.01 | 0.01 | -0.02 | -0.00 | -0.08 | -0.03 | -0.06 | -0.03 | -0.02 |
OPRX News
Will OPRX's OpenPath Deal Help TTD Capture More Healthcare Ad Dollars?
OptimizeRx Brings Net New Authenticated HCP Reach to The Trade Desk Through OpenPath
OptimizeRx: Gross Margin Gains And Improved Long-Term Outlook
Reviewing OptimizeRx (NASDAQ:OPRX) & Aclarion (NASDAQ:ACON)
OptimizeRx Expands Natural Language Audience Builder to Unify HCP and DTC Audience Intelligence
OptimizeRx to Participate in the 10th Annual Lake Street Best Ideas Growth Conference
OptimizeRx Appoints Pharma Commercialization and AI Expert Troy Sarich as Company Advisor
AWM Investment Company Inc. Invests $1.38 Million in OptimizeRx Corp. $OPRX
Dimensional Fund Advisors LP Purchases 102,661 Shares of OptimizeRx Corp. $OPRX
OptimizeRx Q2 Earnings Call Highlights